罗琼 准聘副教授

罗琼，准聘副教授/特聘研究员，博士生导师。

主持多项国家自然科学基金面上项目、青年项目，代表性研究成果发表于Immunity、Nature Communications、Acta Pharmacol Sin、Cell Death Dis、Br J Pharmacol、J Immunol、Int J Nanomedicine、Biochem Pharmacol等期刊。

研究方向为抗炎免疫药理学，主要关注自身免疫性疾病中的免疫细胞和组织细胞，从不同角度阐明炎症进展过程中的新调控机制，发现重要分子节点，在此基础上进行小分子干预，为相关疾病的治疗提供新的切入点和潜在候选化合物。

*first author, #corresponding author

2024

Shi K, Chen K, Lu S, Luo Q#, Xu Q#. G-quadruplex structures in FGFR3 promoter negatively regulate its gene expression and DNA replication. Biochem Biophys Res Commun. 2024 Oct 20;730:150384. 

Yang YQ, Liu YJ, Qiao WX, Jin W, Zhu SW, Yan YX, Luo Q#, Xu Q#. Iguratimod suppresses plasma cell differentiation and ameliorates experimental Sjögren's syndrome in mice by promoting TEC kinase degradation. Acta Pharmacol Sin. 2024 Sep;45(9):1926-1936.

Shi K, Shan Y, Sun X, Chen K, Luo Q#, Xu Q#. TP53INP2 modulates the malignant progression of colorectal cancer by reducing the inactive form of β-catenin. Biochem Biophys Res Commun. 2024 Jan 1;690:149275.

2023

Luo Q#, Liu Y, Shi K, Shen X, Yang Y, Liang X, Lu L, Qiao W, Chen A, Hong D, Sun Y, Xu Q#. An autonomous activation of interleukin-17 receptor signaling sustains inflammation and promotes disease progression. Immunity. 2023 Sep 12;56(9):2006-2020.e6. (Highlighted by Nature Immunology & Immunity)

杨雅琪, 靳伟, 罗琼#,徐强#. 甲氨蝶呤对小鼠实验性干燥综合征的影响. 中国药理学通报 2023; 39(11): 2076-2081.

Before 2023

陈蔼如, 沈燕, 罗琼#,徐强#. 白藜芦醇通过促进活化T 淋巴细胞凋亡改善小鼠实验性自身免疫性脑脊髓炎.中国药理学通报 2022; 38(11): 1627-33.

Chen W, Fang X, Gao Y, Shi K, Sun L, Yu B, Luo Q#, Xu Q#. SBF-1 inhibits contact hypersensitivity in mice through down-regulation of T-cell-mediated responses. BMC Pharmacol Toxicol. 2019 Dec 21;20(1):86. 

Shan Y, Shi K, Qian X, Chang Z, Yang J, Gao Y, Jin W, Luo Q#, Xu Q#. Preclinical development of GR1501, a human monoclonal antibody that neutralizes interleukin-17A. Biochem Biophys Res Commun. 2019 Sep 17;517(2):303-309. 

Shan Y, Gao Y, Jin W, Fan M, Wang Y, Gu Y, Shan C, Sun L, Li X, Yu B, Luo Q#, Xu Q#. Targeting HIBCH to reprogram valine metabolism for the treatment of colorectal cancer. Cell Death Dis. 2019 Aug 13;10(8):618.

Chen W, Qian X, Hu Y, Jin W, Shan Y, Fang X, Sun Y, Yu B, Luo Q#, Xu Q#. SBF-1 preferentially inhibits growth of highly malignant human liposarcoma cells. J Pharmacol Sci. 2018 Dec;138(4):271-278. 

Su H*, Luo Q*, Xie H, Huang XF, Ni YH, Mou YB, Hu QG. Therapeutic antitumor efficacy of tumor-derived autophagosome (DRibble) vaccine on head and neck cancer. Int J Nanomedicine. 2015; 10:1921-30. 

Luo Q*, Sun Y*, Gong FY, Liu W, Zheng W, Shen Y, Hua ZC, Xu Q. Blocking initial infiltration of pioneer CD8(+) T-cells into the CNS via inhibition of SHP-2 ameliorates experimental autoimmune encephalomyelitis in mice. Br J Pharmacol. 2014 Apr;171(7):1706-21. 

Luo Q*, Sun Y*, Liu W, Qian C, Jin B, Tao F, Gu Y, Wu X, Shen Y, Xu Q. A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. J Immunol. 2013 Nov 15;191(10):4969-78. 

Shen Y*, Luo Q*, Xu H, Gong F, Zhou X, Sun Y, Wu X, Liu W, Zeng G, Tan N, Xu Q. Mitochondria-dependent apoptosis of activated T lymphocytes induced by astin C, a plant cyclopeptide, for preventing murine experimental colitis. Biochem Pharmacol. 2011 Aug 1;82(3):260-8. 

Luo Q*, Gu Y*, Zheng W, Wu X, Gong F, Gu L, Sun Y, Xu Q. Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway. Toxicol Appl Pharmacol. 2011 Mar 1;251(2):130-6.